Published on March 12, 2010 at 2:31 AM
Roche Diagnostics (SIX:
RO, ROG; OTCQX: RHHBY) has purchased assets from BioMicro Systems
for all products associated with the Roche NimbleGen microarray
workflow. These assets consist of key instrumentation in the
comprehensive Roche NimbleGen microarray workflow including the
NimbleGen Hybridization Systems (both 4- and 12-bay models). Also
included in this purchase are array accessories covering all mixers
designed for the Roche NimbleGen high-density microarray portfolio.
Roche Diagnostics will continue to provide global sales, service, and
support for all products in the NimbleGen microarray workflows.
With the purchase of these assets, Roche Diagnostics will transfer the
manufacturing capabilities for the above products to an in-house
manufacturing facility. According to Andreas Görtz, VP of Marketing at
Roche NimbleGen, ‘The acquired products are integral to the high quality
data the NimbleGen array workflow provides researchers worldwide.
Acquiring these assets will allow Roche complete control over the
production, support and service of these products to ensure continued
timely distribution, full support and the high level of service our
customers have grown to expect from Roche.”